Clinical trials: Kidney Transplant
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the…
- Conditions
- Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant
- Trial name
- ALLELE (NCT03394365)
- Testing
- tabelecleucel
- Where
- 71 sites in United States, Australia and 7 more
- Volunteers
- 115 people
- Sponsor
- Pierre Fabre Medicament
End Stage Renal Disease
Desensitization Protocol for Highly Sensitized Patients on the Waiting List for Kidney Transplant
The purpose of this study is to determine whether high dose IVIG and B cell depleting agents can be used effectively in highly sensitized wait-listed patients.
- Trial name
- NCT01502267
- Testing
- High dose IVIG and B cell depleting agents
- Where
- South Korea
- Volunteers
- 2 people
- Sponsor
- Seoul National University Hospital
Kidney Transplant, Cardiovascular (CV) Risk
Multimorbidity and Cardiovascular Risk Factors After Renal Transplant
Who can participate? Any adults over the age of 18 who have received a kidney transplant at the research centre are eligible for recruitment within the first month after transplant What does the study involve? The study involves…
- Conditions
- Kidney Transplant, Cardiovascular (CV) Risk, Multimorbidity
- Trial name
- MCaRT (NCT07205692)
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- University Hospitals of Derby and Burton NHS Foundation Trust
Actinic Keratosis
Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients
This is a single arm, open-label interventional study of ingenol mebutate 0.015% in solid organ transplant recipients. The investigators plan to treat 20 subjects, 10 kidney transplant recipients and 10 lung transplant…
- Trial name
- NCT02866695
- Testing
- ingenol mebutate gel 0.015%
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Kidney Transplantation, Kidney Allograft Biopsy
Study of Alloimmune Response in Humoral Rejection After Kidney Transplantation
We will study a prospective cohort including all kidney transplant recipients undergoing kidney graft biopsy in one kidney transplantation center, for a duration of 5 years.
- Conditions
- Kidney Transplantation, Kidney Allograft Biopsy, Humoral Rejection, Microvascular Inflammation
- Trial name
- RECITE (NCT05890430)
- Testing
- Blood draw, Urine draw
- Volunteers
- 570 people
- Sponsor
- University Hospital, Strasbourg, France
Kidney Transplant; Complications, Immunosuppression
The Effects of Microbiota Composition on Immunosuppression Protocols in Transplantation
Solid organ transplantation is the treatment of choice for patients suffering from end-stage organ disease, including for chronic kidney failure.
- Conditions
- Kidney Transplant; Complications, Immunosuppression, Transplant Failure
- Trial name
- NCT04360031
- Testing
- Tacrolimus
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Université Catholique de Louvain
Kidney Transplantation
A Study to Evaluate the Safety and Efficacy of Prograf/FK778 and Prograf/MMF in de Novo Kidney Transplant Recipients
A study to evaluate the safety and efficacy of Prograf/FK778 in de novo kidney transplant patients
- Trial name
- NCT00282230
- Testing
- FK778
- Where
- 23 sites in United States
- Volunteers
- 150 people
- Sponsor
- Astellas Pharma Inc
Medication Adherence, Kidney Transplantation
Teen Adherence in KidnEy Transplant Improving Tracking To Optimize Outcomes - Stage 3
Medication non-adherence is a major problem in kidney transplant recipients; young people 12-24 years of age are at particularly high risk for non-adherence and graft failure compared to young children and adults.
- Trial name
- NCT04288271
- Testing
- Adherence Intervention, Healthy living education intervention
- Where
- 8 sites in United States, Canada
- Volunteers
- 96 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Renal Transplantation
A Pilot Study of Campath-1H Induction Therapy Combined With CellCept® Therapy to Allow for a Calcineurin Inhibitor Free Regimen After Renal Transplantation
The hypothesis of this study is that lymphocyte depletion by Campath-1H and rituximab will obviate the need for long-term calcineurin inhibitors in renal transplantation.
- Trial name
- NCT00214266
- Testing
- Campath 1H®, Rituximab, mycophenolate mofetil
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Wisconsin, Madison
Kidney Transplant; Complications, Rejection of Renal Transplant
Urine CXCL10 Monitoring Trial in Kidney Transplant
This is a Phase II-III multi-center prospective randomized controlled clinical trial of incident adult renal transplant patients.
- Trial name
- NCT03206801
- Testing
- Kidney transplant biopsy
- Where
- 9 sites in Australia, Canada
- Volunteers
- 260 people
- Sponsor
- University of Manitoba
Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
The Effect of Prophylactic Hemodialysis on the Morbidity and Mortality of the Patients With Chronic Kidney Disease Stages 3-4 Undergoing Coronary Artery Graft Bypass
Coronary artery disease is a major cause of death in patients with renal dysfunction Among patients who undergo coronary artery bypass grafting ,renal dysfunction is known To be a major predictor of in-hospital and remote…
- Conditions
- Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Coronary Artery Disease
- Trial name
- NCT01410617
- Testing
- hemodialysis
- Where
- Iran
- Volunteers
- 120 people
- Sponsor
- Imam Khomeini Hospital
Liver Transplantation
RESCUE Study - Everolimus in Liver Transplantation Recipients With Renal Insufficiency
The purpose of the study is to assess the effect of everolimus initiation together with reduction or discontinuation of calcineurin inhibitor (CNI) on renal function in maintenance liver transplant recipients with CNI-related…
- Trial name
- NCT00267189
- Testing
- Everolimus, Calcineurin inhibitors (CNI), Mycophenolate acid (MPA)/ Azathioprine (AZA)
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 145 people
- Sponsor
- Novartis Pharmaceuticals
Renal Transplanted Recipients
SOCRATES: Steroid or Cyclosporine Removal After Transplantation Using Everolimus
The aim of this study is to assess the safety and efficacy of corticosteroid discontinuation versus cyclosporine micro emulsion discontinuation in recipients receiving reduced exposure cyclosporine micro emulsion and…
- Trial name
- NCT00371826
- Testing
- Everolimus (RAD001), Cyclosporine (Calcineurin Inhibitor (CNI)), Methylprednisone/prednisone
- Where
- 7 sites in Australia
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Failure
Immune Monitoring in Sensitized Patients at Risk of Rejection
The purpose of this study is to test the effect of anti-rejection medications on your immune system
- Trial name
- PRISM (NCT03794817)
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- University of California, San Francisco
Renal Transplant Rejection, Kidney Transplant Failure and Rejection
Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation
This is a one year, prospective, randomized, open-label trial examining once versus twice daily tacrolimus dosing regimen using two preparations, extended-release Tacrolimus (Envarsus XR) versus twice daily Tacrolimus (Prograf).
- Trial name
- NCT03511560
- Testing
- Tacrolimus Extended Release Oral Tablet, Tacrolimus
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Columbia University
Complete and Accurate Statistical Data of 60 Patients, CYP3A5*3 Genotypes of 60 Donors and Recipients Were Analyzed Accurately
Analysis of the Effect of Donor CYP3A5 Gene Polymorphism on Early Tacrolimus Concentration and Postoperative Acute Renal Injury After Liver Transplantation
Tacrolimus is the most commonly used immunosuppressant for preventing and treating rejection after liver transplantation. However, its treatment window is narrow, the pharmacokinetic individual differences are large, routine dose…
- Conditions
- Complete and Accurate Statistical Data of 60 Patients, CYP3A5*3 Genotypes of 60 Donors and Recipients Were Analyzed Accurately, Postoperative Tacrolimus Concentrations Were Accurately Recorded in 60 Patients, According to the Diagnosis and Grading Criteria of Acute Kidney Injury, the Cases and Grading of Postoperative Acute Kidney Injury in 60 Patients Were Counted
- Trial name
- NCT06319391
- Testing
- CYP3A5*1*、CYP3A5*1*3, CYP3A5*3*3
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ziqiang Li
Renal Insufficiency
Atorvastatin in the Recipient's Kidney Graft From a Living Donor
Renal insufficiency is a priority disease in the health system, which may require renal replacement therapy based on kidney transplantation, which is considered as therapy of choice.
- Trial name
- ATORV15 (NCT02522117)
- Testing
- Atorvastatin
- Where
- Mexico
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Instituto Mexicano del Seguro Social
The Recipients Undergoing Liver Transplantation
Identification of Genetic Polymorphism Related to Acute Kidney Injury After Liver Transplantation Through Genome-wide Association Study (GWAS) in Korean Population
Some of the liver transplantation recipients experience postoperative acute kidney injury due to various causes including genetic factors.
- Trial name
- NCT03344380
- Where
- South Korea
- Volunteers
- 330 people
- Sponsor
- Yonsei University
Graft Rejection
Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation
The purpose of this research study is to compare the effects of the two most commonly used anti-T cell induction agents(alemtuzumab and rabbit anti-thymocyte globulin) to prevent rejection in kidney and pancreas transplant…
- Trial name
- NCT00331162
- Testing
- Alemtuzumab, Anti-Thymocyte Globulin
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Wake Forest University Health Sciences
Kidney Failure, Chronic
A Simple Clinical Tool for Increasing Enrollment on a Kidney Transplant Waiting List for Patients Aged Over 70 and Initiating Dialysis
The main objective of this study is to show that the systematic use of a prognostic score as early as possible after the initiation of dialysis in patients over 70 years of age and with a good prognosis at 3 years of dialysis…
- Trial name
- KITE (NCT02746146)
- Testing
- Systematic use of a prognostic score
- Where
- 25 sites in France
- Volunteers
- 46 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes